Abstract
The large number of recent public offerings in the USA for spin-off biotechnology companies has prompted debate about whether universities should take a royalty interest in these firms or whether they should own equity in the companies. Based on an analysis of 97 public offerings, the authors argue that universities would be financially better off holding equity (at least in the early stages of a company's life) than in pursuing the more usual royalty agreements.
Get full access to this article
View all access options for this article.